NCT04088721View on ClinicalTrials.gov

Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

July 30, 2020

Study Completion Date

December 11, 2020

Conditions

Allergic Rhinitis

Interventions

BIOLOGICAL

AD17002

LTh(αK) as immunomodulator

OTHER

Formulation Buffer

Formulation buffer

Trial Locations (1)

Unknown

Taipei Medical University, Taipei

Sponsors

Collaborators (1)

Clinipace Worldwide

All Listed Sponsors

collaborator

Clinipace Worldwide

INDUSTRY

collaborator

Taipei Medical University

OTHER

lead

Advagene Biopharma Co. Ltd.

INDUSTRY